Bio

Jean-François Formela is a Partner focused on biopharmaceuticals. He joined Atlas Venture in 1993 to help build the US life sciences franchise. Previously, Jean-Francois was Senior Director, Medical Marketing and Scientific Affairs at Schering-Plough in the US. During his tenure there, he was responsible for the marketing of Intron A, Schering-Plough's alpha-interferon. In his last position at Schering-Plough, he directed the US Phase IV studies in all therapeutic areas, as well as the health economics and biotechnology pre-marketing groups. As a medical doctor, Jean-François practiced emergency medicine at Necker University Hospital in Paris. Since joining Atlas Venture, Jean-François has been involved in the formation of companies such as Adnexus, Archemix, ArQule (NASDAQ: ARQL), Aureon Laboratories, Cellzome, deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM), Resolvyx Pharmaceuticals and SGX Pharmaceuticals (NASDAQ: SGXP). He was also an investor in Achillion (NASDAQ: ACHN) and Nuvelo (NASDAQ: NUVO). Jean-François currently serves on the boards of Atlas portfolio companies ARCA Biopharma, Cellzome, Novexel and Resolvyx Pharmaceuticals. Jean-François is a Trustee of The Boston Institute of Contemporary Art and an Advisor at The Harvard Accelerator Fund. Jean-François received his MD from Paris University School of Medicine and his MBA from Columbia University.